| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51674de58ad1daf2bfa91cdd1b10304d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2217-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2210-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2017-00557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2017-00154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2017-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2210-1433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M3-0283
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2090-0807
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2217-005 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B17-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0604
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B17-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09 |
| filingDate |
2012-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96bbfb64494b298b4bf0ee716e46a2f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_028329047e2ebf3a7dbf74ddd71034b2 |
| publicationDate |
2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3025753-A1 |
| titleOfInvention |
Gnrh antagonists for deacreasing risk of retained pregnancy |
| abstract |
Uterine lavage is performed to withdraw at least 50% of in vivo fertilized preimplantation embryos produced after superovulation of a woman and artificial insemination using sperm of her sexual partner. Subject of the invention is a GnRH antagonist (e.g. cetrotide) alone or combined to a progesterone receptor antagonist (e.g. mifepristone) used for decreasing the risk of retained pregnancy by possibly non-withdrawn embryos. After genetic diagnosis or sex determination or gene therapy, or any combination of any two or more of them, of the recovered embryos and selection of at least one of the embryos to be implanted, the selected embryos are returned to the woman for implantation in her uterus. |
| priorityDate |
2011-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |